GVR Report cover D-dimer Testing Market Size, Share & Trends Report

D-dimer Testing Market Size, Share & Trends Analysis Report By Product, By Test Type, By Method, By Application (Pulmonary Embolism, Deep Vein Thrombosis), By End-use, By Region, And Segment Forecasts, 2020 - 2027

  • Report ID: GVR-4-68039-052-8
  • Number of Pages: 165
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2018
  • Industry: Healthcare

Report Overview

The global D-dimer testing market size was valued at USD 1.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.3% from 2020 to 2027. A paradigm shift towards the demand for next-generation point-of-care D-dimer testing has driven the market. This is because the implementation of POC solutions significantly reduces waiting time, minimizes the length of patient stay, enables faster diagnosis, and results in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE) coupled with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation is increasing the demand for D-dimer testing.

U.K. D-dimer testing market size

As per estimates of the Centers for Disease Control and Prevention (CDC), around 900,000 people are affected with VTE each year and nearly 60,000-100,000 Americans die due to VTE in the U.S. The advent of aptamers that can reduce the use of antibodies for D-dimer testing is proven to be a cost-effective and long-lasting approach in D-dimer testing. Aptamers are also affordable, stable, and faster to produce as well as possess a longer shelf life as compared to antibodies, thus creating lucrative opportunities for market growth. For instance, aptamers provided by Ayass Bioscience, LLC are observed to be useful in homogeneous assays and manual POC agglutination tests. 

Extensive research studies have predicted that elevated D-dimer levels serve as a valuable marker in several clinical conditions, such as atrial fibrillation, HIV infection, coronary artery disease, and acute pancreatitis. For instance, systemic alterations in coagulation are related to complications of acute pancreatitis. Hence, D-dimer levels can be used in the risk assessment of acute pancreatitis. Such research findings are anticipated to broaden the application scope of these tests. 

The effects of heterophilic antibodies on the estimation of the D-dimer level remain a big challenge in the clinical examination of cardiac and other diseases. This results in significant differences in the end results. Studies suggest that the combination of instrumental methods, incorporation of heterophilic antibody blockers along with clinical performance and imaging data can rule out this interference, thus pronouncing the need for further research in this sector.

Product Insights

In terms of revenue, the reagents and consumables segment dominated the market for D-dimer testing with a revenue share of 64.7% in 2019. Frequent purchase rate of reagents and kits along with the availability of a large inventory of ready to use reagents resulted in the estimated revenue share of this segment. In addition, the presence of highly-sensitive automated D-dimer assays that allow the safe exclusion of VTE in minimal time propels the segment growth.

In recent years, automated analyzers have gained immense popularity in the market for D-dimer testing and are anticipated to witness lucrative growth in the coming years. Several research studies have observed that the adoption of these analyzers considerably reduces the laboratory turnaround time and further accelerates clinical decision making. In addition, continuous R&D for expansion of the application scope of analyzers also positively impacts their usage rate.

For instance, in February 2019, Radiometer Limited stated that its AQT90 FLEX analyzers were successfully assessed for the D-dimer POCT in suspected lower limb deep vein thrombosis cases. The implementation of the AQT90 FLEX analyzer provided results in less than 21 minutes and had a significant impact on improving patient experience. The introduction of novel products or an extension of the products in POC settings is expected to drive the market for D-dimer testing.

Test Type Insights

The clinical laboratory tests segment dominated the market for D-dimer testing in 2019 and accounted for a revenue share of 61.6%. Highly sensitive D-dimer assays are commonly used for the exclusion of VTE and the management of disseminated intravascular coagulation. Conjugated use of these assays with a diagnostic algorithm inclusive of compression ultrasound and a pretest probability have shown greater success rate in clinical practices, which significantly contributes to segment growth.

Point-of-care (POC) tests are expected to witness the fastest growth rate in the near future owing to the emergence of several automated solutions that are ideal for near-patient testing. Intelligent design, user-friendly features, minimal maintenance, lower risk of biohazard and errors, and reduced turnaround time are among the few benefits associated with the usage of POC solutions. 

The constant development of numerous rapid POC tests further drives segment progression. Besides, the availability of highly sensitive tests developed on the principle of immunofiltration technology generates results within minutes. Similarly, rapid, automated, and quantitative enzyme immunoassays-based tests are commercially available for D-dimer testing.

Method Insights

Enzyme-linked Immunosorbent Assays (ELISA) held the largest revenue share of 36.0% in 2019 because it is a standard method for D-dimer testing. The advent of faster, automated, and highly sensitive modified ELISA assays have overcome the challenges pertaining to conventional ELISA assays as the latter are labor-intensive and time-consuming. Thus, the introduction of automated ELISA assays, such as the VIDAS  assay of bioMérieux SA, is driving the segment growth.

The fluorescence immunoassay segment is projected to witness the fastest CAGR throughout the forecast period owing to a rise in the demand for automated fluorescence immunoassay-based solutions for D-dimer testing. These products based on fluorescence immunoassay methodology operate as precise, user-friendly, and reproducible platforms in POC settings.

The advantage of fluorescence immunoassays includes higher sensitivity of nearly 100%, simpler assay designs, and the use of simplified reagents. Some of the products based on fluorescence immunoassays include the Triage D-Dimer Test of Quidel Corporation, and AFIAS-6 system and ichroma reader provided by BODITECH MED INC.

Application Insights

The Deep Vein Thrombosis (DVT) segment dominated the D-dimer testing market and accounted for a revenue share of 37.6% in 2019. DVT is a common medical condition that often goes undiagnosed and affects mostly hospitalized patients due to immobility. This leads to a rise in the incidence of DVT and an increased risk of complications associated with it. According to research studies, more than 200,000 people develop venous thrombosis every year in the U.S.

The risk of developing DVT is high in patients who have undergone different types of surgeries. Research studies have reported that patients undergoing spinal interbody fusion are highly vulnerable to develop lower limb DVT. DVT also results in longer hospital admission and drug treatment that can last for a few months, which subsequently adds to the total healthcare cost. Thus, early management of DVT is crucial, which raises the demand for D-dimer testing on a large scale.

D-dimer tests are used as a diagnostic test for acute disseminated intravascular coagulation (DIC). Despite the wide usage of these tests, there is limited data on the specificity of these tests in the diagnosis of acute DIC. Thus, continuous research and the advent of POC tests are expected to drive their utilization rate in the near future. Besides, early diagnosis of DIC facilitates sepsis management, which expands the adoption rate of D-dimer testing at the fastest CAGR for DIC. 

End-use Insights

The hospital segment captured the largest end-use share of 36.3% in 2019 owing to a rise in the hospital admission rates with an increase in the number of pulmonary embolism cases globally. In addition, as per the estimates of the British Lung Foundation, around half of the patients tend to develop a pulmonary embolism while they are hospitalized.

Several studies have proved that pulmonary embolism is the third most common cause of mortality in hospitalized patients. Most of the autopsy studies have also revealed that around 60% of patients affected by pulmonary embolism died in hospitals. This high incidence rate of pulmonary embolism cases and the high mortality rate due to pulmonary embolism leads to large-scale adoption of D-dimer testing in hospitals. 

Global D-dimer testing market share

The diagnostic centers segment is anticipated to register a lucrative growth rate as these entities provide tests at a lower cost as compared to hospitals. Moreover, decreased patient wait time and improved patient satisfaction have led to great interest among the patients to undergo rapid POC D-dimer testing in diagnostic centers.

Regional Insights

North America dominated the market for D-dimer testing with a revenue share of 33.2% in 2019. A large number of publications related to the applications of D-dimer expand the clinical utility of the coagulation testing in this region. Recently, a study published in January 2020, stated that the D-dimer protocol is beneficial in the identification of VTE of neurosurgical patients, and acts as a practical and cost-effective approach in VTE diagnosis.

The presence of regulatory guidelines for the management of VTE further propels the demand for coagulation tests in North America. The American Society of Hematology 2018 guidelines are intended to support the healthcare professionals and patients for the VTE diagnosis. These guidelines are based on the updated and original systematic reviews collected from researches, which further assess the evidence and make recommendations for VTE diagnosis.

In the Asia Pacific, the market for D-dimer testing is anticipated to witness the fastest growth rate during the forecast period due to the presence of supportive guidelines for coagulation tests laid down by the government and private organizations. The pathology manuals of the Royal College of Pathologists of Australasia (RCPA) provide useful guidelines for D-dimer testing. These manuals assist the healthcare providers and facilitate the interpretation of results, which surges the demand for these tests.

Key Companies & Market Share Insights

Key players are adopting strategic growth initiatives to reinforce their product offerings and maintain a competitive edge in the market for D-dimer testing. In addition, key players are involved in the development of sensitive as well as automated hemostasis markers for the expansion of market potential. For instance, in April 2019, Ortho Clinical Diagnostics, a U.S.-based company, launched its D-Dimer assay in collaboration with Diazyme Laboratories, Inc. This new assay is one of the latest product of MicroTip Partnership Assay Program of Ortho Clinical, which allow the company to provide high value, flexible, quick, and esoteric testing solutions. This product launch expanded the company’s expertise to offer innovative assay to its customers. Some of the prominent players in the D-dimer testing market include:

  • Thermo Fisher Scientific Inc.

  • F. Hoffmann-La Roche Ltd.

  • Siemen Healthineers

  • Abbott

  • biomérieux SA


  • HORIBA, Ltd.

  • Quidel Corporation

  • Diazyme Laboratories, Inc.

  • Biomedica Diagnostics

  • Sekisui Diagnostics

D-dimer Testing Market Report Scope

Report Attribute


Market size value in 2020

USD 1.3 billion

Revenue forecasts in 2027

USD 1.7 billion

Growth rate

CAGR of 4.3% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Product, test type, method, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; France; Spain; Italy; Japan; China; India; Brazil; Mexico; Saudi Arabia; South Africa

Key companies profiled

Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Siemen Healthineers; Abbott; biomérieux SA; WERFEN; HORIBA, Ltd.; Quidel Corporation; Diazyme Laboratories, Inc.; Biomedica Diagnostics; Sekisui Diagnostics

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global D-dimer testing market report on the basis of product, test type, method, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2027)

    • Analyzers

    • Reagents & Consumables

  • Test Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Clinical Laboratory Tests

    • Point-of-Care Tests

  • Method Outlook (Revenue, USD Million, 2016 - 2027)

    • Enzyme-linked Immunosorbent Assay (ELISA)

    • Latex-enhanced Immunoturbidimetric Assays

    • Fluorescence Immunoassays

    • Others

  • Application Outlook (Revenue, USD Million, 2016 - 2027)

    • Deep Vein Thrombosis (DVT)

    • Pulmonary Embolism (PE)

    • Disseminated Intravascular Coagulation (DIC)

    • Others

  • End-use Outlook (Revenue, USD Million, 2016 - 2027)

    • Hospitals

    • Academic & Research Institutes

    • Diagnostic Centers

    • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • The U.S.

      • Canada

    • Europe

      • The U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa (MEA)

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.